Non-small Cell Lung Cancer Therapeutics Market To Reach $43.89 Billion By 2030

Non-small Cell Lung Cancer Therapeutics Market Growth & Trends

The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

 Request a free sample copy or view report summary: Non-small Cell Lung Cancer Therapeutics Market Report

Non-small Cell Lung Cancer Therapeutics Market Report Highlights

• The adenocarcinoma segment dominated the market in 2023 with a share of 43.3% in 2023 due to increase in the population consuming tobacco and other products for smoking.

• The targeted therapy segment dominated the market in 2023 with a share of 50.5% in 2023. The factors responsible for the market growth are the benefits of this therapy such as increased number of targeted therapeutics and low percentage of side effects during the treatment.

• The hospital pharmacy segment dominated the market in 2023 with a share of 66.7% in 2023. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC.

• North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.4% in 2023. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments.

Non-small Cell Lung Cancer Therapeutics Market Segmentation

Grand View Research has segmented the global non-small cell lung cancer therapeutics market on the basis of on type, treatment, distribution channel, and region:

Non-small Cell Lung Cancer Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Squamous Cell Carcinoma

• Large Cell Carcinoma

• Adenocarcinoma

• Others

Non-small Cell Lung Cancer Therapeutics Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Targeted Therapy

• Immunotherapy

Non-small Cell Lung Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Drug Store and Retail Pharmacy

• Online Pharmacy

Non-small Cell Lung Cancer Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Non-small Cell Lung Cancer Therapeutics Market

• F. Hoffmann-La Roche Ltd.

• Mylan N.V.

• Teva Pharmaceutical Industries Ltd.

• Sanofi

• Pfizer Inc.

• GSK plc

• Novartis AG

• Bayer AG

• Eli Lilly and Company

• Merck & Co., Inc.